Annual report pursuant to Section 13 and 15(d)

Cancer Genetics, Inc. Merger (Details Narrative)

v3.23.1
Cancer Genetics, Inc. Merger (Details Narrative) - USD ($)
$ / shares in Units, $ in Thousands
 12 Months Ended
Mar. 30, 2021
Aug. 21, 2020
Dec. 31, 2022
Dec. 31, 2021
Feb. 23, 2021
Business Acquisition [Line Items]          
Common Stock, Par or Stated Value Per Share     $ 0.0001 $ 0.0001  
Business combination, acquisition related costs     $ 2,310  
Estimated useful life     10 years    
Revenue percentage description     Key assumptions in this analysis included an estimated 10% annual customer attrition rate based on historical vivoPharm operations, a blended U.S. federal, state and Australian income tax rate of 27.1%, a present value factor of 8.5% as well as revenue, cost of revenue and operating expense assumptions regarding the future growth, operating expenses, including corporate overhead charges, and required capital investments    
Common Stock [Member]          
Business Acquisition [Line Items]          
Stock issued during period, shares, new issues     121,000    
StemoniX [Member]          
Business Acquisition [Line Items]          
Intangible assets related to Merger, recognized $ 9,500   $ 9,500    
StemoniX [Member] | Merger Agreement [Member]          
Business Acquisition [Line Items]          
Stock issued during period, shares, new issues 160,942        
Business combination consideration transferred $ 59,900        
StemoniX [Member] | Merger Agreement [Member] | Common Stock [Member]          
Business Acquisition [Line Items]          
Stock issued during period, shares, new issues 2,201,437        
Business combination, step acquisition, equity interest in acquiree, fair value $ 50,740        
StemoniX [Member] | Merger Agreement [Member] | Common Stock Warrants [Member]          
Business Acquisition [Line Items]          
Stock issued during period, shares, new issues 431,537        
Business combination, step acquisition, equity interest in acquiree, fair value $ 9,040        
StemoniX [Member] | Merger Agreement [Member] | Common Stock Options [Member]          
Business Acquisition [Line Items]          
Stock issued during period, shares, new issues 11,181        
Business combination, step acquisition, equity interest in acquiree, fair value $ 139        
StemoniX [Member] | Holders [Member] | Merger Agreement [Member]          
Business Acquisition [Line Items]          
Stock issued during period, shares, new issues   3,595,508      
Common Stock, Par or Stated Value Per Share   $ 0.0001      
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award   178,356      
Share-Based Payment Arrangement, Option, Exercise Price Range, Lower Range Limit   $ 3.30      
Share-Based Payment Arrangement, Option, Exercise Price Range, Upper Range Limit   $ 23.05      
StemoniX [Member] | Investor [Member] | Merger Agreement [Member]          
Business Acquisition [Line Items]          
Share-Based Compensation Arrangement by Share-Based Payment Award, Shares Purchased for Award   28,778      
Shares Issued, Price Per Share   $ 29.5295 $ 29.5295   $ 29.5295
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member]          
Business Acquisition [Line Items]          
Business combination, acquisition related costs       $ 2,300  
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Trade Names [Member]          
Business Acquisition [Line Items]          
Intangible assets related to Merger, recognized     $ 1,500    
Estimated useful life     10 years    
StemoniX and Cancer Genetics Inc [Member] | Merger Agreement [Member] | Customer Relationships [Member]          
Business Acquisition [Line Items]          
Intangible assets related to Merger, recognized     $ 8,000    
Royalty payment percentage     1.00%